{"id":227258,"date":"2017-07-12T11:55:22","date_gmt":"2017-07-12T15:55:22","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/foundation-medicine-announces-timing-for-second-quarter-2017-business-wire-press-release.php"},"modified":"2017-07-12T11:55:22","modified_gmt":"2017-07-12T15:55:22","slug":"foundation-medicine-announces-timing-for-second-quarter-2017-business-wire-press-release","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/molecular-medicine\/foundation-medicine-announces-timing-for-second-quarter-2017-business-wire-press-release.php","title":{"rendered":"Foundation Medicine Announces Timing for Second Quarter 2017 &#8230; &#8211; Business Wire (press release)"},"content":{"rendered":"<p><p>    CAMBRIDGE, Mass.--(BUSINESS    WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today    announced that financial results for the company's second    quarter ended June 30, 2017 will be released on Tuesday, August    1, 2017. The management team will host a conference call on    Tuesday, August 1, 2017, at 4:30 p.m. ET to discuss the    company's financial results and recent developments. The call    can be accessed by dialing 1-877-270-2148 (domestic) or    1-412-902-6510 (international) five minutes prior to the start    of the call. A passcode is not required to access the live call    from either number. A replay of the conference call will be    available until August 15, 2017 and can be accessed by dialing    1-412-317-0088 and providing the passcode 10110537.  <\/p>\n<p>    The live, listen-only webcast of the conference call may be    accessed by visiting the investors section of the company's    website at investors.foundationmedicine.com. A replay of the    webcast will be available shortly after the conclusion of the    call and will be archived on the company's website for two    weeks following the call.  <\/p>\n<p>    About Foundation Medicine    Foundation Medicine (NASDAQ:FMI) is a molecular information    company dedicated to a transformation in cancer care in which    treatment is informed by a deep understanding of the genomic    changes that contribute to each patients unique cancer. The    company offers a full suite of comprehensive genomic profiling    assays to identify the molecular alterations in a patients    cancer and match them with relevant targeted therapies,    immunotherapies and clinical trials. Foundation Medicine's    molecular information platform aims to improve day-to-day care    for patients by serving the needs of clinicians, academic    researchers and drug developers to help advance the science of    molecular medicine in cancer. For more information, please    visit <a href=\"http:\/\/www.FoundationMedicine.com\" rel=\"nofollow\">http:\/\/www.FoundationMedicine.com<\/a> or follow    Foundation Medicine on Twitter (@FoundationATCG).  <\/p>\n<p>    Foundation Medicineis a registered    trademark of Foundation Medicine, Inc.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>See original here:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.businesswire.com\/news\/home\/20170712005264\/en\/Foundation-Medicine-Announces-Timing-Quarter-2017-Financial\" title=\"Foundation Medicine Announces Timing for Second Quarter 2017 ... - Business Wire (press release)\">Foundation Medicine Announces Timing for Second Quarter 2017 ... - Business Wire (press release)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's second quarter ended June 30, 2017 will be released on Tuesday, August 1, 2017.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/molecular-medicine\/foundation-medicine-announces-timing-for-second-quarter-2017-business-wire-press-release.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[26],"tags":[],"class_list":["post-227258","post","type-post","status-publish","format-standard","hentry","category-molecular-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/227258"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=227258"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/227258\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=227258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=227258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=227258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}